Patents by Inventor Doron Eren
Doron Eren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10689415Abstract: Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.Type: GrantFiled: April 19, 2018Date of Patent: June 23, 2020Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Avigdor Scherz, Yoram Salomon, Efrat Rubinstein, Alexander Brandis, Doron Eren, Karin Neimann
-
Publication number: 20180305405Abstract: Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.Type: ApplicationFiled: April 19, 2018Publication date: October 25, 2018Inventors: Avigdor SCHERZ, Yoram SALOMON, Efrat RUBINSTEIN, Alexander BRANDIS, Doron EREN, Karin NEIMANN
-
Patent number: 10087474Abstract: A fed-batch fermentation method is for production of bacteriochlorophyll a (Bchla) from Rhodovulum sulfidophilum. The growth medium contains an inorganic nitrogen compound as a nitrogen source. During fermentation, the growth medium is supplemented with a succinate carbon source, an inorganic compound nitrogen source and a phosphorous source from external reservoirs connected to the fermenter vessel. After completion of the fermentation, Bchla is recovered from the separated cells.Type: GrantFiled: March 11, 2014Date of Patent: October 2, 2018Assignee: TOOKAD IP SARLInventors: Doron Eren, Nitsa Mazor
-
Patent number: 9957293Abstract: Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.Type: GrantFiled: April 16, 2012Date of Patent: May 1, 2018Assignee: YEDA RESEARCH AND DEVELOPMENT COMPANY LTD.Inventors: Avigdor Scherz, Yoram Salomon, Efrat Rubinstein, Alexander Brandis, Doron Eren, Karin Neimann
-
Publication number: 20160024542Abstract: A fed-batch fermentation method is for production of bacteriochlorophyll a (Bchla) from Rhodovulum sulfidophilum. The growth medium contains an inorganic nitrogen compound as a nitrogen source. During fermentation, the growth medium is supplemented with a succinate carbon source, an inorganic compound nitrogen source and a phosphorous source from external reservoirs connected to the fermenter vessel. After completion of the fermentation, Bchla is recovered from the separated cells.Type: ApplicationFiled: March 11, 2014Publication date: January 28, 2016Inventors: Doron Eren, Nitsa Mazor
-
Patent number: 9119885Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radioimaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for targeted chemotherapy.Type: GrantFiled: February 7, 2014Date of Patent: September 1, 2015Assignee: Steba Biotech S.A.Inventors: Doron Eren, Tamar Yechezkel, Yoseph Salitra, Natalia Koudinova
-
Publication number: 20140154181Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radioimaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for targeted chemotherapy.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: STEBA BIOTECH S.A.Inventors: Doron EREN, Tamar YECHEZKEL, Yoseph SALITRA, Natalia KOUDINOVA
-
Patent number: 8673270Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radio imaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for in targeted chemotherapy.Type: GrantFiled: October 22, 2009Date of Patent: March 18, 2014Assignee: Steba Biotech S.A.Inventors: Doron Eren, Tamar Yechezkel, Yoseph Salitra, Natalia Koudinova
-
Publication number: 20120294801Abstract: Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.Type: ApplicationFiled: April 16, 2012Publication date: November 22, 2012Applicant: Yeda Research and Development Co., Ltd.Inventors: Avigdor Scherz, Yoram Salomon, Efrat Rubinstein, Alexander Brandis, Doron Eren, Karin Neimann
-
Patent number: 8207154Abstract: The invention provides cationic tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one positively charged group and/or at least one basic group that is converted to a positively charged group under physiological conditions, preferably Bchls having an onium group derived from a N-containing aliphatic or heterocyclic radical such as ammonium, guanidinium, imidazolium, pyridinium, and the like or a phosphonium, arsonium, oxonium, sulfonium, selenonium, telluronium, stibonium, or bismuthonium group, or a basic group that is converted to such onium groups under physiological conditions, said groups being bound to one or more of the positions 17<3>, 13<3> and 3<2> of the Bchl molecule by ester or amide bond. The Bchls are useful for photodynamic therapy and diagnosis.Type: GrantFiled: June 7, 2005Date of Patent: June 26, 2012Assignee: Yeda Research and Development Co., Ltd.Inventors: Avigdor Scherz, Alexander Brandis, Yoram Salomon, Doron Eren, Avraham Cohen
-
Publication number: 20110250144Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radio imaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for in targeted chemotherapy.Type: ApplicationFiled: October 22, 2009Publication date: October 13, 2011Applicant: STEBA BIOTECH N.V.Inventors: Doron Eren, Tamar Yechezkel, Yoseph Salitra, Natalia Koudinova
-
Publication number: 20080138278Abstract: Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and normeoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.Type: ApplicationFiled: August 23, 2007Publication date: June 12, 2008Applicant: Yeda Research & Development Co., Ltd.Inventors: Avigdor Scherz, Yoram Salomon, Efrat Rubinstein, Alexander Brandis, Doron Eren, Karin Neimann
-
Publication number: 20080076748Abstract: The invention provides cationic tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one positively charged group and/or at least one basic group that is converted to a positively charged group under physiological conditions, preferably Bchls having an onium group derived from a N-containing aliphatic or heterocyclic radical such as ammonium, guanidinium, imidazolium, pyridinium, and the like or a phosphonium, arsonium, oxonium, sulfonium, selenonium, telluronium, stibonium, or bismuthonium group, or a basic group that is converted to such onium groups under physiological conditions, said groups being bound to one or more of the positions 17<3>, 13<3> and 3<2> of the Bchl molecule by ester or amide bond. The Bchls are useful for photodynamic therapy and diagnosis.Type: ApplicationFiled: June 7, 2005Publication date: March 27, 2008Inventors: Avigdor Scherz, Alexander Brandis, Yoram Salomon, Doron Eren, Avraham Cohen
-
Patent number: 7084244Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N?(?-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N?(?-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.Type: GrantFiled: September 12, 2002Date of Patent: August 1, 2006Assignee: DeveloGen Israel Ltd.Inventors: Chaim Gilon, Doron Eren, Irina Zeltser, Alon Seri-Levy, Gal Bitan, Dan Muller
-
Publication number: 20030144186Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N&agr;(&ohgr;-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N&agr;(&ohgr;-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.Type: ApplicationFiled: September 12, 2002Publication date: July 31, 2003Inventors: Chaim Gilon, Doron Eren, Irina Zeltser, Alon Seri-Levy, Gal Bitan, Dan Muller
-
Patent number: 6407059Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N&agr;(&ohgr;-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N&agr;(&ohgr;-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.Type: GrantFiled: May 31, 2000Date of Patent: June 18, 2002Assignee: Peptor LimitedInventors: Chaim Gilon, Doron Eren, Irina Zeltser, Alon Seri-Levy, Gal Bitan, Dan Muller
-
Patent number: 6265375Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N&agr;(&ohgr;-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N&agr;(&ohgr;-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.Type: GrantFiled: July 22, 1998Date of Patent: July 24, 2001Assignees: Yissum Research Development Co. of the Hebrew University, Peptor LimitedInventors: Chaim Gilon, Doron Eren, Irina Zeltser, Alon Seri-Levy, Gal Gitan, Dan Muller
-
Patent number: 5883293Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup..alpha. (.omega.-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup..alpha. (.omega.-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.Type: GrantFiled: December 5, 1996Date of Patent: March 16, 1999Assignees: Peptor Ltd., Yissum Research Development Co. of the Hebrew UniversityInventors: Chaim Gilon, Doron Eren, Irina Zeltser, Alon Seri-Levy, Gal Bitan, Dan Muller
-
Patent number: 5874529Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup..alpha. (.omega.-functionalized)amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup..alpha. (.omega.-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.Type: GrantFiled: December 5, 1996Date of Patent: February 23, 1999Assignees: Peptor Ltd., Yissum Research Development Company of the Hebrew UniversityInventors: Chaim Gilon, Doron Eren, Irina Zeltser, Alon Seri-Levy, Gal Bitan, Dan Muller
-
Patent number: 5811392Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup..alpha. (.omega.-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup..alpha. (.omega.-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.Type: GrantFiled: June 7, 1995Date of Patent: September 22, 1998Assignees: Yissum research Development Co. of the Hebrew University, Peptor LimitedInventors: Chaim Gilon, Doron Eren, Irina Zeltser, Alon Seri-Levy, Gal Bitan, Dan Muller